A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

On 21 December of last year, the Danish pharmaceutical company experienced a 21% plunge in its share price following disappointing trial results for its new obesity drug, CagriSema. Amycretin is ...

The phase Ib/IIa study evaluated the safety, tolerability, pharmacokinetics and proof-of-concept of three doses of amycretin in obesity patients ... of action of the drugs. Wegovy contains ...

Novo Nordisk (NYSE:NVO) shares are rallying 6.87% to $86.67 as of 10:27 AM ET Friday, after the company reported promising trial results for its new obesity drug, amycretin. Warning! GuruFocus has ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...

Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, ...